樂普醫療(300003.SZ)：人工智能“心電圖機”(OmniECGB120AI)獲NMPA註冊批准
格隆匯 7 月 30日丨樂普醫療(300003.SZ)公佈，公司AI事業部下屬全資子公司深圳市凱沃爾電子有限公司自主研發的具備人工智能深度學習分析算法的“心電圖機”(OmniECGB120AI)獲得國家藥品監督管理局(以下簡稱“NMPA”)的註冊批准。該產品是公司推出的國內外首款使用AI芯片進行心電圖人工智能自動分析的心電圖設備，填補了我國人工智能心電圖機的產品空白，是繼今年1月首獲NMPA批准的人工智能醫療產品(AI-ECGPlatform)之後，公司獲得的又一項人工智能NMPA三類醫療註冊證。
心電圖是心血管疾病最簡單、快捷、經濟的臨牀檢查方法，是心血管疾病檢驗的基石。樂普人工智能“心電圖機”(OmniECGB120AI)是在嵌入式AI芯片基礎上，通過集成已經獲得NMPA註冊批准的心電人工智能分析軟件(AI-ECGPlatform)算法的一款智能心電圖機，其最大優勢就是能夠在一個心電圖設備上，實現心電圖採集，快速準確的AI自動分析，打印報告的心電圖檢查全部工作流程。通過同步採集心電信號，可自動分析成人心律失常、心肌梗塞、心室肥大和ST-T異常等心血管疾病。該設備的AI算法基於人工智能深度學習技術，使用了數千萬級別的心電圖大數據進行訓練，總體準確率達95%以上。樂普的AI-ECG技術在海內外申報了多項發明專利，其中3個專利已經授權。
樂普人工智能“心電圖機”(OmniECGB120AI)獲批後，將快速實現在國內醫院、個體診所、體檢中心、社康中心、養老機構等醫療機構進行商業化推廣應用，既解決了國內大量缺乏專業心電醫生的問題，又解放了大型醫院專業心電醫生的勞動力，切實提高工作效率，提升診斷水平，形成一體化的人工智能心電分析診斷技術服務鏈，實現患者在這些醫療機構的屬地化、快速化心電分析和診斷，滿足相關醫療服務的剛性需求，切實造福國內廣大的心血管疾病患者。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
